Beam Therapeutics (BEAM) boosts Q1 revenue and advances late-stage gene-editing pipeline
Rhea-AI Filing Summary
Beam Therapeutics reported first quarter 2026 results alongside major clinical milestones. License and collaboration revenue rose to $31.7 million, up from $7.5 million a year earlier, while net loss narrowed to $94.3 million or $0.91 per share. Cash, cash equivalents and marketable securities totaled $1.2 billion as of March 31, 2026, supporting a projected cash runway into mid-2029.
Clinically, updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showed rapid, durable increases in total and functional AAT and a well‑tolerated safety profile, leading Beam to select 60 mg as the optimal biological dose and plan a pivotal expansion cohort in the second half of 2026 under an accelerated approval pathway. In sickle cell disease, Phase 1/2 BEACON data for risto-cel were published in The New England Journal of Medicine, and Beam expects to submit a biologics license application as early as year‑end 2026.
Beam also plans an IND filing for BEAM-304 in phenylketonuria and initial 2026 data for BEAM-301 in glycogen storage disease type Ia, while an ongoing healthy volunteer trial of BEAM-103 is expected to complete dosing in the first half of 2026.
Positive
- None.
Negative
- None.
Insights
Beam couples strong cash runway with advancing late‑stage gene‑editing programs.
Beam reports Q1 2026 license and collaboration revenue of $31.7M, sharply higher than $7.5M a year earlier, while net loss narrowed to $94.3M. With $1.2B in cash and securities as of March 31, 2026, management projects funding into mid‑2029.
On the pipeline, BEAM‑302 in AATD has Phase 1/2 data showing rapid, durable AAT increases and good tolerability up to 75 mg, with a 60 mg dose chosen for a pivotal cohort and an FDA‑discussed accelerated approval path. Risto‑cel in sickle cell disease has peer‑reviewed BEACON data and a targeted BLA submission as early as year‑end 2026.
Together, a late‑stage SCD asset, a pivotal‑bound AATD program, and emerging BEAM‑301/304 liver programs create multiple shots on goal backed by long cash runway. Actual value realization will depend on pivotal BEAM‑302 results, successful risto‑cel filing and review, and continued safety and manufacturing performance across these gene‑editing therapies.
8-K Event Classification
Key Figures
Key Terms
alpha-1 antitrypsin deficiency medical
biologics license application regulatory
base editing technical
phenylketonuria medical
glycogen storage disease type Ia medical
accelerated approval pathway regulatory
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
(Address of principal executive offices) |
|
|
|
(Zip Code) |
(Registrant’s telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release Issued by Beam Therapeutics Inc. on May 7, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BEAM THERAPEUTICS INC. |
|
|
|
|
|
Date: May 7, 2026 |
|
By: |
/s/ John Evans |
|
|
Name: |
John Evans |
|
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026
Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026
Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026
Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029
Cambridge, Mass., May 7, 2026 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.
“The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming a commercial-stage company. The updated topline data from BEAM-302 – including robust increases in total AAT and a well-tolerated safety profile – give us high confidence in the 60 mg optimal biological dose and a clear path to initiating the pivotal cohort in the second half of this year,” said John Evans, chief executive officer of Beam Therapeutics. “Publication of the BEACON trial data in the New England Journal of Medicine underscores the differentiated profile of risto-cel, and we remain on track to submit our BLA as early as year-end 2026, a milestone toward bringing a potentially transformative treatment to patients with sickle cell disease. With BEAM-304 in PKU, we are extending the reach of our clinically validated base editing platform to directly correct disease-causing mutations in a new indication, further demonstrating the breadth of what precision genetic medicine can achieve. With a strong cash position extending our runway into mid-2029, we have the financial foundation to execute across all of these priorities and deliver on our mission to bring precision genetic medicines to patients who need them most.”
First Quarter 2026 and Recent Progress and Anticipated Milestones
Corporate
Liver-targeted Genetic Disease Franchise
BEAM-302: Beam’s lead genetic disease program is designed to be a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.
BEAM-304: BEAM-304 leverages Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU).
BEAM-301: BEAM-301 aims to correct the most common disease-causing mutation, R83C, in patients with glycogen storage disease type Ia (GSDIa).
Hematology Franchise
Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD).
Next-generation Programs in Sickle Cell Disease and Hematology:
First Quarter 2026 Financial Results
Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of March 31, 2026, which includes $100 million from the close of the company’s financing agreement with Sixth Street, along with an anticipated additional $100 million from the Sixth Street facility, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU, ESCAPE and GSDIa; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304; our planned submission of a BLA for risto-cel; our expected presentations at upcoming medical conferences, including at ATS 2026; our anticipated regulatory interactions and filings; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Josie Butler
1AB
josie@1abmedia.com
Condensed Consolidated Balance Sheet Data (unaudited) |
|
|||||||
(in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
March 31, |
|
|
December 31, |
|
||
Cash, cash equivalents, and marketable securities |
|
$ |
1,211,652 |
|
|
$ |
1,245,210 |
|
Total assets |
|
|
1,480,798 |
|
|
|
1,481,177 |
|
Total liabilities |
|
|
316,360 |
|
|
|
242,819 |
|
Total stockholders’ equity |
|
|
1,164,438 |
|
|
|
1,238,358 |
|
Condensed Consolidated Statement of Operations (unaudited) |
|
|||||||
(in thousands, except share and per share data) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
Three Months Ended March 31, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
License and collaboration revenue |
|
$ |
31,738 |
|
|
$ |
7,470 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
104,524 |
|
|
|
98,816 |
|
General and administrative |
|
|
34,429 |
|
|
|
27,940 |
|
Total operating expenses |
|
|
138,953 |
|
|
|
126,756 |
|
Loss from operations |
|
|
(107,215 |
) |
|
|
(119,286 |
) |
Other income (expense): |
|
|
|
|
|
|
||
Change in fair value of derivative liabilities |
|
|
2,500 |
|
|
|
3,200 |
|
Change in fair value of non-controlling equity investments |
|
|
16 |
|
|
|
(2,081 |
) |
Change in fair value of contingent consideration liabilities |
|
|
514 |
|
|
|
(27 |
) |
Interest and other income (expense), net |
|
|
9,867 |
|
|
|
9,864 |
|
Total other income (expense) |
|
|
12,897 |
|
|
|
10,956 |
|
Net loss |
|
$ |
(94,318 |
) |
|
$ |
(108,330 |
) |
Unrealized gain (loss) on marketable securities |
|
|
(2,181 |
) |
|
|
(519 |
) |
Comprehensive loss |
|
$ |
(96,499 |
) |
|
$ |
(108,849 |
) |
Net loss per common share, basic and diluted |
|
$ |
(0.91 |
) |
|
$ |
(1.23 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
103,262,001 |
|
|
|
87,975,311 |
|